Muscular Dystrophy Treatment Market: Growth, Development, Trends, Demand, Share, Analysis and Forecast 2026
Muscular Dystrophy
is characterized by a collection of muscle-wasting conditions. The
disorder is caused by genetic mutations which interfere with the
production of muscle protein dystrophin, necessary to build muscles.
Muscular dystrophy is a genetic disease, consequently, the chance of
an individual developing a disease increases with a history of
muscular dystrophy in the family. The symptoms include shortening of
muscles and tendons, the curvature of spine, weakening of heart
muscles leading to cardiac problems, and breathing problems. The most
common forms of muscular dystrophies include duchenne muscular
dystrophy, becker muscular dystrophy, myotonic disease, congenital
disease and oculopharyngeal muscular dystrophy. The cure for any form
of muscular dystrophy is currently unspecified, but the symptoms can
be relived through physical therapy, exercise, rehabilitative devices
like a powered wheelchair, respiratory care and surgery.
Request For
Sample Copy of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/914
The common
muscular dystrophy types:
-
Duchenne muscular dystrophy (DMD)
Most common form of muscular dystrophy in children
caused by lack of protein dystrophin. The onset of symptoms is seen
at the age of 3, generally wheelchair-bound by 12. The Curvature in
spine, heart, and lungs effects are the symptoms. Duchenne muscular
dystrophy (DMD) is an X-linked disease predominantly affecting males,
resulting in uniform muscle wasting. Death occurs due to respiratory
failure by mid-twenties.
-
Becker muscular dystrophy(BMD)
Similar to Duchenne,
however, with later onset and slow progression of the illness. Death
occurs in the mid-forties.
Molecular
therapy segment is expected to generate larger revenue with higher
efficiency in clinical trials
The global muscular dystrophy treatment market is
segmented on the basis of treatment, diagnosis, end user and
geography.
Specific
guidance by FDA is expected to dominate North America the global
market
Regional segmentation of the global muscular
dystrophy treatment market by Coherent Market Insights comprises
North America, Latin America, Europe, Asia-Pacific and The Middle
East and Africa. According to the Centers for Disease Control and
Prevention estimates in 2007, 349 out of 2.37 million males aged 5 to
24 years were reported to have duchenne muscular dystrophy or
becker muscular dystrophy in the United States.
North America is expected to dominate the global muscular dystrophy
treatment market owing to the absence of marketed pharmacological
therapies indicated to treat muscular dystrophy, rising prevalence of
the disease and rising research and development for producing
effective drugs. Europe is expected to boost the market share in the
forecast period with the growing public awareness and increasing
research activities.
Launch of efficient corticosteroids to
rise the market demand
The key players
operating the global muscular dystrophy treatment market include
Santhera Pharmaceuticals, PTC Therapeutics, BioMarin Pharmaceutical,
Sarepta Therapeutics and Eli Lilly. The approval and launch of oral
corticosteroid Emflaza in 2017, has been found highly effective in
patients to regain strength and restore their ability to walk. The
other vendors include Acceleron Pharma, Capricor Therapeutics,
Bristol-Myers Squibb, Lexicon Pharmaceuticals, and Pfizer.
Download The PDF
Brochure of This Business Report:
https://www.coherentmarketinsights.com/insight/request-pdf/914
About
Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Comments
Post a Comment